Value of whole body 18FDG-PET to identify the active site of gestational trophoblastic neoplasia.
Tony Dhillon(Chelsea and Westminster Hospital), Michael J. Seckl(Charing Cross Hospital), Peter Schmid(St Bartholomew's Hospital), Carlo Palmieri(University of Liverpool), Philip Savage(Institute of Infection and Immunity), E.S. Newlands(Charing Cross Hospital), Ian Lindsay(Primary Children's Hospital), J. Frank, Neil J. Sebire(Great Ormond Street Hospital)
PubMed
November 1, 2006
Cited by 46
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2013|379
The value of standards for health datasets in artificial intelligence-based applications
|Nature Medicine|2023|268